Amneal Pharmaceuticals

AMRX

Market cap $4.18B

BRIDGEWATER, N.J., April 14, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (Nasdaq: AMRX) today announced the U.S. launch of albuterol sulfate inhalation aerosol and beclomethasone dipropionate HFA inhalation aerosol, two widely prescribed respiratory products that were approved by the Food and Drug Administration (FDA) in 2025. These are the Company's first two metered-dose inhalation (MDI) product launches in the U.S., marking Amneal's entry into the complex inhalation category.

Amneal Pharmaceuticals heads into 2026 with diversified growth drivers, rising margins and a faster launch cadence supporting steady revenue expansion.

Amneal Pharmaceuticals trades below peers on sales multiple despite strong gains, with a $14 target hinging on execution, mix shift, and margin strength.

Amneal Pharmaceuticals taps GLP-1 growth via a Pfizer-linked manufacturing deal, gaining exposure without clinical risks while scaling injectables and peptides.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

BRIDGEWATER, N.J., April 09, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) today announced the launch of bimatoprost ophthalmic solution 0.01% (2.5 mL, 5 mL and 7.5 mL).

BRIDGEWATER, N.J., April 07, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”), today announced that the Company will release its first quarter 2026 financial results on Friday, May 1, 2026, prior to market open. The Company will host an audio webcast at 8:30 a.m. ET.

BRIDGEWATER, N.J., April 07, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (Nasdaq: AMRX) today announced donations totaling $2 million to multiple patient assistance foundations supporting individuals living with Parkinson's disease (PD) in recognition of Parkinson's Awareness Month.

The U.S. Food and Drug Administration said on Friday it has notified manufacturers of certain Parkinson's disease treatments to ​update their prescribing information with a new warning about ‌a potential risk of seizures.

Amneal Pharmaceuticals, Inc. remains a Buy, with 45-55% upside potential and a $5-6bn market cap target in my opinion. AMRX delivered strong 2025 results—revenue up to $3.02bn, operating income $421m, and net leverage reduced to 3.5x. 2026 guidance is mixed: 1-4% revenue growth, but 5-10% adjusted EBITDA and 12-24% EPS growth, with division performance diverging.